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Introduction
Gastric cancer is the fourth most common malignancy worldwide [1],
and most common malignancy in Korea [2]. Although survival time has
been lengthened, the life expectancy of advanced disease still remains
within one year.
For patients with advanced gastric carcinoma or recurrent cancer, the
response rate (RR) for first-line chemotherapy ranges from 33-55%, and
the survival time following chemotherapy is superior to that of patients
given best supportive care [3]. Despite poorer survival benefit and toler-
ance of second-line chemotherapy, about 20% of patients with failure of
first-line chemotherapy receive second-line chemotherapy [4]. Asian stud-
ies have reported a RR of second-line chemotherapy as 5-25% and pro-
gression-free survival (PFS) of 5.2-8.8 months [5,6]. Many clinicians
consider second-line chemotherapy after failure of first-line chemotherapy
for patients with advanced gastric carcinoma.
There is a controversy about the benefit of sequential salvage therapy
further to second-line. However, with prolonged survival time of patients
and tolerable toxicity of drugs, there has been renewed interest in
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Purpose
The aims of this study are to find out whether the sequence of chemotherapeutic regimens in-
cluding second- and third-line taxane and irinotecan influences the survival of patients with un-
resectable gastric carcinoma and to identify clinical characteristics of patients with improved
response.
Materials and Methods
Fifty gastric carcinoma patients who were treated by third-line sequential chemotherapy between
November 2004 and July 2010 were enrolled in this study. Their overall survival (OS) and time to
progression (TTP) were set up as primary and secondary end points. For the sequence of
chemotherapy regimen, two arms were used. Arm A was defined as 5-fluorouracil (5-FU)+cisplatin
(FP) or folinic acid, 5-FU and oxaliplati (FOLFOX), followed by folinic acid, 5-FU and irinotecan
(FOLFIRI), and paclitaxel or docetaxel plus 5-FU, with or without epirubicin. Arm B was defined as
FP or FOLFOX, followed by paclitaxel or docetaxel plus 5-FU, and FOLFIRI.
Results
The median OS of all patients was 16.0 months (95% confidence interval, 13.6 to 18.3 months),
which is longer than historical control of patients who did not receive third-line chemotherapy.
The sequence of second and third-line regimen, including irinotecan and taxane, did not present
significant difference in OS or TTP after failure of 5-FU with platinum chemotherapy. In survival
analysis of patients’ clinicopathologic characteristics, poor prognosis was shown in patients with
poorly differentiated histologic features, elevated serum carcinoembryonic level, and shorter TTP
of first line chemotherapy.
Conclusion
It is possible for patients to respond differently to chemotherapy due to differences in clinical fea-
tures and underlying gene expression profiles. Development of individualized chemotherapy reg-
imens based on gene expression profiles is warranted.
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chemotherapy after failure of second-line treatments. It has been our em-
piric observation that some patients maintain good performance after fail-
ure  of  second-line  chemotherapy,  and  live  longer  with  salvage
chemotherapy than other patients with supportive care. However, few
studies have been conducted on third-line and sequential therapy.
The aim of the present study was to clarify the relationship between
the sequence of second- and third-line chemotherapy regimen including
taxane and irinotecan with survival of patients, and to identify clinical
characteristics of patients with better response to salvage chemotherapy
than others.
M ater ials  and  M eth od s
1. Patients
We retrospectively evaluated the medical records of advanced or re-
curred gastric carcinoma patients who were diagnosed and treated at
Gangnam Severance Hospital between November 2004 and July 2010.
Patients who met the following criteria were eligible: histologically proven
advanced gastric adenocarcinoma with metastatic or recurrent disease;
received third-line chemotherapy at Gangnam Severance Hospital using
folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) or 5-
FU+cisplatin (FP), folinic acid, 5-FU and irinotecan (FOLFIRI), paclitaxel
or docetaxel with 5-FU, with or without epirubicin; measurable lesion ac-
cording to the Response Evaluation Criteria in Solid Tumors (RECIST)
or a non-measurable lesion, assessed using either computed tomography
(CT) or magnetic resonance imaging; 18-75 years of age; Eastern Coop-
erative Oncology Group (ECOG) performance status≤2; life expectancy
of at least 3 months; and adequate hematologic function, evident as ab-
solute neutrophil count≥1500/ʼL, platelet count≥100,000/ʼL, hepatic
function (total bilirubin≤2 times the upper normal limit [UNL], serum
transaminase level≤2 times the UNL) and renal function (serum crea-
tine≤1.5 times the UNL). Exclusion criteria were the presence of other
severe medical illness, central nervous system metastasis, another active
malignancy, or history of anaphylaxis to drugs. The protocols were re-
viewed and approved by Yonsei University Health System Institutional
Review Board.
Clinical information included gender, age at diagnosis, ECOG per-
formance status, pathologic differentiation, Lauren classification, coex-
isting peritoneal or hepatic metastases, date of chemotherapy, and number
of cycles. In addition, laboratory data including hemoglobin, serum albu-
min, carcinoembryonic antigen (CEA), and cancer antigen (CA) 19-9
were also reviewed. Tumor responses were evaluated according to the
RECIST guidelines.
2. Treatment
Sequential chemotherapy was defined as chemotherapy using more
than two different chemotherapeutic regimens performed consecutively.
Patients were assigned to either arm A or arm B, according to the sequence
of three chemotherapeutic regimens. Arm A comprised FOLFOX or FP
for first-line chemotherapy; FOLFIRI for second-line chemotherapy; and
docetaxel or paclitaxel, leucovorin, and 5-FU (with or without epirubicin)
for third-line chemotherapy. In arm B, patients were treated with FOL-
FOX or FP for first-line chemotherapy; docetaxel or paclitaxel, leucovorin,
and FU with or without epirubicin for second-line chemotherapy; and
FOLFIRI for third-line chemotherapy.
1) FOLFOX chemotherapy
Patients received oxaliplatin (100 mg/m2in 500 mL normal saline) or
5% dextrose water over 2 hours followed by leucovorin (100 mg/m2) over
2 hours on day 1 and continuous infusion of 5-FU 1,000 mg/m2/day for
2 days. The cycle was repeated every two weeks.
2) FP chemotherapy
Cisplatin (70 mg/m2 in 500 mL normal saline) or 5% dextrose water
was intravenously administered over 2 hours on day 1 followed by con-
tinuous infusion of 5-FU (1,000 mg/m2/day) for 2 days. The cycle was
repeated every three weeks.
3) FOLFIRI chemotherapy
Irinotecan (150 mg/m2 in 500 mL normal saline) was intravenously
administered over 2 hours on followed by leucovorin (100 mg/m2over 2
hours) on day 1 and 5-FU (1,000 mg/m2/day) as a continuous infusion
for 2 days. The cycle was repeated every two weeks.
4) Docetaxel or paclitaxel, leucovorin, and 5-FU chemotherapy, with
or without epirubicin
Docetaxel (75 mg/m2 in 500 mL normal saline) or paclitaxel (175
mg/m2in 500 mL normal saline) was intravenously administered over 2
hours followed by leucovorin (100 mg/m2over 2 hours) on day 1 and 5-
FU (1,000 mg/m2/day) as a continuous infusion for 2 days. The cycle was
repeated every 3 weeks. For some patients, epirubicin (50 mg/m2in 100
mL normal saline) was intravenously administered over 30 minutes on
day 2.
5) Efficacy
Response was assessed after two cycles of chemotherapy and when
disease progression was clinically suspected. A measurable lesion was
defined as a lesion with the longest diameter ≥10 mm in any dimension
assessed by spiral CT imaging. Tumor response was evaluated accordingCancer Res Treat. 2011;43(4):236-243
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to the RECIST guidelines as follows: complete response (CR) if all target
lesions disappeared, partial response (PR) if the sum of diameters of the
target lesions decreased by at least 30%, progressive disease (PD) if the
sum of the longest diameters of the target lesions increased by at least
20% and one or more new lesions appeared, and stable disease (SD) for
responses that were neither PR nor PD. The assessment was done by CT
scan. The RR was defined as proportion of the patients with responses of
CR or PR out of all patients.
3. Statistical analyses
Overall survival (OS) was defined as the interval from the first date of
chemotherapy to death or the last follow-up date. Time to progression
(TTP) was defined as the time from the first date of chemotherapy to the
time of progression of the disease or the last follow-up date. The Kaplan-
Meier method was used for survival analysis, and survival curves were
compared assessed using the log-rank test. Following variables were in-
cluded in univariate analysis: age at diagnosis, gender, performance status
by ECOG criteria, pathologic differentiation, coexisting peritoneal or he-
patic metastases, type of chemotherapeutic regimen, hemoglobin, serum
albumin, CEA, CA19-9, and TTP of first- or second-line chemotherapy.
For variables with a probability p-value≤0.3 in univariate analysis, mul-
tivariate analysis was also performed using the Cox’s proportional hazard
regression model (two-sided). All statistical tests were two-sided, with p-
values≤0.05 considered significant.
R esults
1. Baseline characteristics
Between November 2004 and July 2010, 50 patients with gastric car-
cinoma were treated with a sequential chemotherapy protocol, based only
on FOLFOX or FP, FOLFIRI, and paclitaxel or docetaxel, at Gangnam
Severance Hospital. The baseline characteristics of the patients are pre-
sented in Table 1. The median age was 52.5 years (range, 29 to 70 years),
and 34 patients (68%) were male. Forty subjects (80%) had good per-
formance status (ECOG 0-1). Seven patients had diffuse type, 13 patients
had interstitial type, and the other two patients had mixed type adenocar-
cinoma. No significant difference except for peritoneal carcinomatosis
was observed. 
ECOG, Eastern Cooperative Oncology Group; WD-MD, adenocarcinoma, well differentiated and adenocarcinoma, moderate differentiated; PD-
SRC, adenocarcinoma, poorly differentiated and signet ring cell carcinoma. a)p-values from Pearson’s ˇ2test, except for age (Kruskal-Walis test).
Table 1. Baseline characteristics of the patients
Variables
Arm A (n=18)  Arm B (n=32)
p-value 
No.                   % No.          % 
Gender
Male 11 61.1 23 71.9 0.434
Female 7 38.9 9 28.1
Median age (range, yr) 53.0 (41-70) 52.5 (29-70)
Disease status
Advanced or metastatic 14 77.8 23 71.9 0.648
Recurred 4 22.2 9 28.1
ECOG
02 11.1 2 6.3 0.437
1 11 61.1 25 78.1
25 27.8 5 15.6
Pathology
WD-MD 6 33.3 11 34.4 0.941
PD-SRC 12 66.7 21 65.6
Liver metastasis
Yes 2 11.1 6 18.8 0.479
No 16 88.9 26 81.2
Peritoneal metastasis
Yes 15 83.3 12 37.5 0.002
No 3 16.7 20 62.5Ji Soo Park, Sequential Chemotherapy for Gastric Cancer
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OS, overall survival; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; WD-MD, adenocarcinoma, well differentiated and
adenocarcinoma, moderate differentiated; PD-SRC, adenocarcinoma, poorly differentiated and signet ring cell carcinoma; CEA, carcinoembryonic
antigen; CA, cancer antigen; TTP, time to progression. a)Hemoglobin≤13 g/dL in men, ≤12 g/dL in woman, b)Serum albumin≤3.4 g/dL, c)Serum
CEA≥5 ng/mL, d)Serum CA19-9≥35 U/mL.
Table 2. Survival analysis according to baseline characteristics
OS                                                   Univariate analysis  Multivariate analysis
Variables No. (95% CI, mo) Relative risk p-value Relative risk p-value
(95% CI) (95% CI)
Gender
Male 34 20.5 (14.3-26.7) 1 0.491
Female 16 14.5 (8.6-20.3) 0.777 (0.379-1.596)
Age (yr)
＜Median value 25 16.4 (9.6-23.3) 1 0.467
≥Median value 25 15.4 (13.5-17.4) 1.297 (0.642-2.619)
Disease status
Recurred 13 38.7 (38.7-38.7) 1 0.208
Advanced or metastatic 37 15.4 (13.4-17.5) 1.757 (0.722-4.279)
ECOG
Good (0-1) 40 17.1 (10.8-23.5) 1 0.81
Poor (2) 10 15.7 (9.2-22.2) 1.117 (0.454-2.750)
Pathologic differentiation
WD-MD 17 29.6 (16.9-42.3) 1 0.024 1 ＜0.001
PD-SRC 33 13.9 (10.8-17.0) 2.327 (1.096-4.940) 5.784 (2.307-14.500)
Hepatic metastasis
Present 8 28.3 (3.3-53.2) 1 0.372
Absent 42 15.4 (12.9-18.0) 1.544 (0.591-4.034)
Peritoneal metastasis
Present 27 16.4 (12.3-20.6) 1 0.793
Absent 23 16.0 (7.6-24.4) 1.095 (0.556-2.157)
Hemoglobin
Normal 16 16.4 (14.6-18.2) 1 0.845
Decreaseda) 34 16.0 (8.6-23.3) 1.073 (0.530-2.173)
Serum albumin
Normal 44 16.4 (10.8-22.0) 1 0.168
Decreasedb) 6 11.5 (10.1-12.8) 1.962 (0.739-5.211)
Serum CEA
Normal 29 20.0 (12.2-27.7) 1 0.259 1 0.002
Elevatedc) 19 16.4 (11.4-21.4) 1.499 (0.739-3.042) 3.694 (1.609-8.482)
Serum CA19-9
Normal 24 20.0 (13.1-26.8) 1 0.261
Elevatedd) 20 14.7 (8.1-21.2) 1.546 (0.720-3.321)
TTP under first-line 
chemotherapy
＜Median value (5 mo) 26 21.6 (7.8-35.3) 1 0.001 1 ＜0.001
≥Median value (5 mo) 24 11.5 (7.8-15.1) 3.342 (1.597-6.997) 7.248 (2.931-17.925)
TTP under second-line 
chemotherapy
＜Median value (3 mo) 28 15.4 (11.6-19.3) 1 0.769
≥Median value (3 mo) 22 16.4 (13.7-19.1) 1.107 (0.562-2.180)Cancer Res Treat. 2011;43(4):236-243
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2. Treatment outcomes
Fifty patients received median fourth-line chemotherapy (range, 3 to
10), and a median of 18 cycles (range, 4 to 60 cycles) were administered.
Median OS of all patients was 16.0 months (95% confidence interval [CI],
13.6 to 18.3 months) (Fig. 1), and median TTP was 5.0 months (95% CI,
3.9 to 6.1 months) in first-line chemotherapy, 2.4 months (95% CI, 1.6 to
3.2 months) in second-line chemotherapy, and 2.5 months (95% CI, 1.8
to 3.3 months) in third-line chemotherapy.
The median OS time of arm A and arm B was 17.1 months (95% CI,
10.7 to 23.6 months), and 15.4 months (range, 13.8 to 17.1 months), re-
spectively. The difference was not significant (p=0.950) (Fig. 1).
TTP of arm A and arm B with first-line chemotherapy was 5.5 months
(95% CI, 1.2 to 9.8 months) and 4.8 months (95% CI, 3.8 to 5.8 months),
respectively (p=0.064). For the second-line chemotherapy, TTP of arm A
and arm B was 2.7 months and 2.2 months, respectively (p=0.850). Each
TTP of the two groups were 2.2 months in arm A and 2.7 months in arm
B (p=0.297). These data did not show significant differences. 
In addition, we analyzed clinicopathologic characteristics of the pa-
tients. Patients with poorly-differentiated adenocarcinoma or signet ring
cell feature showed poorer prognosis than others. Furthermore, elevated
CEA level and shorter TTP of first-line chemotherapy were significantly
related with shorter survival times (Table 2).
3. Efficacy
The RR was 50% for first-line chemotherapy, 8% for second-line
chemotherapy, and 8.5% for third-line chemotherapy. RR of first-line
chemotherapy was 50% in both arms. In second-line chemotherapy, RR
was 11.1% in arm A and 6.3% in arm B. In third-line chemotherapy, RR
was 6.3% in arm A and 9.7% in arm B. The disease control rate (DCR)
Values are presented as number (%). CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Table 3. Response to sequential chemotherapy of the two groups
Chemotherapy
1st line 2nd line 3rd line
Arm A Arm B Arm A Arm B Arm A Arm B
CR 3 (16.7) --- --
PR 6 (33.3) 16 (50.0) 2 (11.1) 2 (6.3) 1 (6.3) 3 (9.7)
SD 7 (38.9) 9 (28.1) 5 (27.8) 15 (46.9) 3 (18.8) 10 (32.3)
PD 2 (11.1) 7 (21.9) 11 (61.1) 15 (46.9) 12 (75.0) 18 (58.1)
Fig. 1. Overall survival by treatment Arm. Fig. 2. Overall survival by response to chemotherapy.Ji Soo Park, Sequential Chemotherapy for Gastric Cancer
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which was determined by the disease status (CR, PR, or SD) controlled
by treatment, of first-line chemotherapy was 88.9% in arm A and 78.1%
in arm B (p=0.342). In second-line chemotherapy, DCR of arm A was
38.9%, and that of arm B was 53.1% (p=0.333). In third-line chemother-
apy, DCR was 25% in arm A and 41.9% in arm B (p=0.252). These results
showed no significant differences (Table 3). 
Twenty-one patients did not show any response (PR or CR) to any of
the three sequential chemotherapies. They were grouped as poor-respon-
ders. The other 29 patients were classified as good-responders. The me-
dian  OS  was  20.0  months  (95%  CI,  2.4  to  37.5  months)  in  the
good-responders and 13.9 months (95% CI, 12.0 to 15.8 months) in the
poor-responders. The difference was significant (p=0.028) (Fig. 2).
Discussion
It has generally been accepted that palliative chemotherapy can signif-
icantly prolong survival of patients with advanced gastric carcinoma,
longer than best supportive care [7]. Platinum-based chemotherapy is
widely-used as first-line chemotherapy for advanced gastric cancer. Given
the reported tolerance and survival benefits of second-line chemotherapy
[4], studies have sought to identify the benefit and adequate regimen of
second-line chemotherapy.
The current study evaluated two groups of gastric cancer patients who
received third-line chemotherapy. Previous studies reported the median
PFS of 2.5-3.3 months and the median OS of 5.3-8.7 months in gastric
cancer patients who received second-line chemotherapy [6,8-10]. In this
study, the median PFS was 2.4 months (95% CI, 1.6 to 3.2 months) for
patients treated with second-line chemotherapy, similar to the previous
report. The median OS was 16.0 months (95% CI, 13.6 to 18.3 months),
and 32.0% of patients survived after 2 years. These times were slightly
longer than that of historical control. We suggest that this is due to sequen-
tial treatment of the patients.
This study included a restricted population with a performance status
that permitted the use of third-line chemotherapy after failure of second-
line chemotherapy. Therefore, this result was subject to limitation in com-
parison  with  other  survival  data  of  patients  without  third-line
chemotherapy. Nevertheless, based on 2.5 months of median TTP in third-
line chemotherapy, the authors suggest that third-line chemotherapy would
provide a survival benefit for patients with favorable performance status.
In many phase II clinical trials of second-line chemotherapy for ad-
vanced gastric cancer, RR was about 20.8%, and DCR was about 51%
[4]. In the present study, RR for second-line chemotherapy was 8% and
DCR was 48%. Considering only third-line chemotherapy, RR was 8.5%
and DCR 36.2%. 
There is still little information to support the provision of a second-line
chemotherapeutic regimen after failure of platinum-based first-line
chemotherapy.
Satoh et al. [11] reported that sequential chemotherapy appears to be
both a feasible and effective treatment for advanced gastric cancer. Their
sequential protocol was S-1 based chemotherapy for first-line chemother-
apy, a low dose irinotecan/cisplatin for second-line chemotherapy, and
paclitaxel for third-line chemotherapy. Thirty-two gastric cancer patients
showed relatively long median survival (17.4 months; 95% CI, 323 to
723 days). This result shows that a consecutive use of chemotherapy has
a substantial impact on OS of gastric cancer patients. These facts also
demonstrate that second- and third-line chemotherapy is necessary to treat
advanced gastric cancer.
Many clinicians consider the FOLFIRI regimen and paclitaxel or do-
cetaxel with 5-FU regimen as second-line chemotherapy after failure of
platinum-based first line chemotherapy [4]. Numerous physicians sug-
gested that FOLFIRI is tolerable and has a modest effect as a second-line
chemotherapy for gastric carcinoma. In an Asian study, the median PFS
was 3.2 months, and the median OS was 9.1 months [12]. In another study,
RR was 18.2%, median OS was 5.1 months, and median TTP was 2.3
months [13]. On the other hand, the tolerance and effectiveness of tax-
ane-based chemotherapy apparent in several studies (median TTP, 2.6-
3.9  months;  median  OS,  7.2  to  10.1  months)  warrants  its  use  as
second-line chemotherapy in advanced gastric carcinoma [10,14].
Kim et al. [15] reported that overall RR and DCR for patients with do-
cetaxel/cisplatin followed by FOLFIRI and patients with FOLFIRI fol-
lowed by a docetaxel/cisplatin regimen showed no significant difference.
However, to the best of our knowledge, survival benefits according to se-
quence of regimens of second-line and third-line chemotherapy after fail-
ure of first line chemotherapy have not been reported.
In this study, we analyzed 50 patients treated with either FOLFOX or
FP chemotherapy followed by FOLFIRI, and paclitaxel or docetaxel, or
FOLFOX or FP chemotherapy followed by paclitaxel or docetaxel, and
FOLFIRI regimen. The median OS and TTP showed no difference re-
gardless of sequence. However, we found some patients responded better
to chemotherapy, and their OS was longer than the others. Previous in-
vestigators suggested that low hemoglobin level [8,9], low serum albumin
level [16,17], high CEA level [17], poor performance status [8-10,16,17],
shorter TTP of first-line chemotherapy [9,17], shorter TTP of second-line
chemotherapy [16], and poor differentiation of tumor [10,16] are poor
prognostic factors for patients with gastric carcinoma under sequential
chemotherapy. We analyzed the previously reported factors and found
some differences in survival according to histologic differentiation, ele-
vated CEA level, and TTP of first line chemotherapy in this study.
There has been a controversy regarding the influence of the histological
feature of signet ring cell on the prognosis of gastric carcinoma. Some re-
searchers reported poorer prognosis of advanced gastric carcinoma with
signet ring cell histology [16,18], while better prognosis of early gastric
carcinoma with signet ring cell histology has been reported [19]. In this
study, gastric adenocarcinoma with poorly differentiated or signet ring
cell features had poorer response to sequential chemotherapy, and had
shorter median OS than well or moderately differentiated ones. Concern-
ing CEA level, some investigators reported the relationship of serum CEA
level with tumor invasion [20], lymph node metastasis, and higher recur-
rence rate [21]. 
Herein, we suggest that differences in gene and protein expressions are
other prognostic values that should be taken into account. In a recent study,Cancer Res Treat. 2011;43(4):236-243
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the regulation of different pathways in histologically different carcinomas
was reported [22]. We suppose that there are some genetic differences in
diffuse gastric adenocarcinoma and that the different genetic defect influ-
ences a poorer response to sequential chemotherapy. Furthermore, CEA
is a widely used tumor marker, and the CEA gene has been widely-used
as a tumor-specific promoter and target of treatment over the last decade
[23].
We propose that the difference in response could also be attributed to
the differences in gene expression profiles between the two groups. In re-
cent years, it has become clear that a pharmacogenic approach is a poten-
tial tool for optimizing treatment for several human tumors [24]. The
ability of genetic polymorphisms to influence pharmacogenetics of 5-FU,
platinum derivatives, anthracyclines, irinotecan, and docetaxel in gastric
cancer has been reported. The use of multiple gene analyses in the devel-
opment of individualized gastric cancer chemotherapies could be helpful
in selecting patients who are more likely to benefit better to a particular
therapy. The possible prediction of cancer outcome from gene expression
classifiers, sets of genes, or signatures associated with prognosis together
with classification rules has been suggested [25].
Limitations of this study include the retrospective study design and
small patient pool. Nevertheless, the results of this study provides evidence
that third-line chemotherapy, including FOLFOX or FP, FOLFIRI, pa-
clitaxel or docetaxel regimen, helps to improve OS of patients, regardless
of the sequence of use of taxane and irinotecan. In addition, OS seems to
be poorly affected by poorly differentiated or signet ring cell feature of
adenocarcinoma, elevated CEA level, and shorter TTP of first-line
chemotherapy. 
C onclusion
Different chemotherapy-responses to locally advanced or metastatic
gastric carcinoma treated with second and third-line chemotherapy using
irinotecan or taxane could be attributed not to sequence of chemothera-
peutic regimen, but to patients’ different clinical features underlying dif-
ferent  gene  expression  profiles.  Development  of  individualized
chemotherapy-based regimens based on multiple gene analysis is war-
ranted. Future studies will be required to investigate the impact of genetic
difference on response to sequential chemotherapy.
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